

EXHIBIT 3

From: [Brett A. Postal](#)
To: [Kayali, Kathryn](#); [Neil B. McLaughlin](#); "Mascherin, Terri L."
Cc: [Patel, Priyata](#); [Mike Cottler](#); [Shaun Van Horn](#); [laurafairney@quinnemanuel.com](#); [John R. Labbe](#); [Argall, Arthur](#); [M710 Team](#); [Jamie.Obrien@steptoe-johnson.com](#); [Gordon.Copland@steptoe-johnson.com](#); [DG-Aflibercept](#); [WFG-aflibercept@willkie.com](#); [mhissam@hfdrlaw.com](#); [Carl Shaffer](#); [Andrew Robey](#); [Max Gottlieb](#); [QE - Samsung Bioepis](#); [skl@schraderlaw.com](#); [clt@simmermanlaw.com](#); [fes@simmermanlaw.com](#); [trey@simmermanlaw.com](#); [SERVICE - Formycon Team](#); [MGB-Amgen-ABP938](#); [ABP938](#); [regeneronpatent@lists.kellogghansen.com](#); [drpogue@cdkrlaw.com](#); [sruby@cdkrlaw.com](#); [Ashley Hardesty Odell](#); [Kaitlyn McKittrick](#); [Eylea Biosimilars](#); [Eylea](#)
Subject: RE: In re aflibercept - May 10 submission m/c
Date: Tuesday, May 28, 2024 7:35:52 PM

Counsel,

We write to follow up on an item raised by counsel for Samsung Bioepis during the meet and confer today.

In the spirit of compromise and given the Court's Order today limiting Regeneron's preliminary injunction motions to the '865 patent, Amgen is willing to agree to have the parties serve on Amgen redacted, non-confidential versions of the parties' preliminary and permanent injunction briefing, supporting declarations and any other supporting papers, and deposition transcripts of Regeneron witnesses limited to papers addressing or relating to the '865 patent. Amgen would request that such documents be served no later than June 5, 2024, and Amgen would reserve its right to seek redacted versions of all papers related to Regeneron's other asserted patents at a later date following completion of its preliminary injunction proceeding.

Please let us know by COB tomorrow whether the parties are amenable to this proposal. If not, as mentioned in my email of Friday, Amgen intends to file with the Court a motion for expedited access to the previously requested judicial records.

Regards,
Brett



Brett A. Postal
901 New York Avenue, NW
Suite 900 East
Washington, D.C. 20001

Main Number: 202.783.6040
Fax Number: 202.783.6031
Email: bpostal@rothwellfigg.com
Website: www.rothwellfigg.com

The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst & Manbeck, P.C. immediately at (202) 783-6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any attachments.

-----Original Message-----

From: Kayali, Kathryn <KKayali@wc.com>

Sent: Tuesday, May 28, 2024 9:59 AM

To: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com>; 'Mascherin, Terri L.' <TMascherin@jenner.com>; Brett A. Postal <bpostal@rothwellfigg.com>
Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van Horn <vanhorn@fr.com>; laurafairneny@quinnemanuel.com; John R. Labbe <jlabbe@marshallip.com>; Argall, Arthur <aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-Aflibercept@netorg8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938 <ABP938@rothwellfigg.com>; regeneronpatent@lists.kelloggghansen.com; drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea <Eylea@wc.com>
Subject: RE: In re aflibercept - May 10 submission m/c

All:

Regeneron is available at 1PM today to address the proposal regarding sealed filings and Friday's filing. Please circulate a dial in.

Best,

Kat

From: Neil B. McLaughlin <NMcLaughlin@rmmslegal.com<mailto:NMcLaughlin@rmmslegal.com>>
Date: Monday, May 27, 2024 at 9:55 PM
To: 'Mascherin, Terri L.' <TMascherin@jenner.com<mailto:TMascherin@jenner.com>>, Brett A. Postal <bpostal@rothwellfigg.com<mailto:bpostal@rothwellfigg.com>>
Cc: Patel, Priyata <Priyata.Patel@weil.com<mailto:Priyata.Patel@weil.com>>, Mike Cottler <mcottler@geminilaw.com<mailto:mcottler@geminilaw.com>>, Shaun Van Horn <vanhorn@fr.com<mailto:vanhorn@fr.com>>, laurafairneny@quinnemanuel.com <laurafairneny@quinnemanuel.com<mailto:laurafairneny@quinnemanuel.com>>, John R. Labbe <jlabbe@marshallip.com<mailto:jlabbe@marshallip.com>>, Argall, Arthur <aargall@wc.com<mailto:aargall@wc.com>>, M710 Team <M710Team@rmmslegal.com<mailto:M710Team@rmmslegal.com>>, Jamie.Obrien@steptoe-johnson.com <Jamie.Obrien@steptoe-johnson.com<mailto:Jamie.Obrien@steptoe-johnson.com>>, Gordon.Copland@steptoe-johnson.com <Gordon.Copland@steptoe-johnson.com<mailto:Gordon.Copland@steptoe-johnson.com>>, DG-Aflibercept <DG-Aflibercept@netorg8512690.onmicrosoft.com<mailto:DG-Aflibercept@netorg8512690.onmicrosoft.com>>, WFG-aflibercept@willkie.com <WFG-aflibercept@willkie.com<mailto:WFG-aflibercept@willkie.com>>, mhissam@hfdrlaw.com <mhissam@hfdrlaw.com<mailto:mhissam@hfdrlaw.com>>, Carl Shaffer

<cshaffer@hfdrlaw.com<mailto:cshaffer@hfdrlaw.com>>, Andrew Robey
<arobey@hfdrlaw.com<mailto:arobey@hfdrlaw.com>>, Max Gottlieb
<mgottlieb@hfdrlaw.com<mailto:mgottlieb@hfdrlaw.com>>, QE - Samsung Bioepis <qe-
samsungbioepis@quinnemanuel.com<mailto:qe-samsungbioepis@quinnemanuel.com>>,
skl@schraderlaw.com <skl@schraderlaw.com<mailto:skl@schraderlaw.com>>,
clt@simmermanlaw.com <clt@simmermanlaw.com<mailto:clt@simmermanlaw.com>>,
fes@simmermanlaw.com <fes@simmermanlaw.com<mailto:fes@simmermanlaw.com>>,
trey@simmermanlaw.com <trey@simmermanlaw.com<mailto:trey@simmermanlaw.com>>,
SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com<mailto:SERVICE-
Formycon_Team@fr.com>>, MGB-Amgen-ABP938 <MGB-Amgen-
ABP938@marshallip.com<mailto:MGB-Amgen-ABP938@marshallip.com>>, ABP938
<ABP938@rothwellfigg.com<mailto:ABP938@rothwellfigg.com>>,
regeneronpatent@lists.kellogghansen.com
<regeneronpatent@lists.kellogghansen.com<mailto:regeneronpatent@lists.kellogghansen.com>>,
drpogue@cdkrlaw.com <drpogue@cdkrlaw.com<mailto:drpogue@cdkrlaw.com>>,
sruby@cdkrlaw.com <sruby@cdkrlaw.com<mailto:sruby@cdkrlaw.com>>, Ashley Hardesty Odell
<ahardestyodell@bowlesrice.com<mailto:ahardestyodell@bowlesrice.com>>, Kaitlyn McKitrick
<kmckitrick@bowlesrice.com<mailto:kmckitrick@bowlesrice.com>>, Eylea Biosimilars
<Eylea.Biosimilars@weil.com<mailto:Eylea.Biosimilars@weil.com>>, Eylea
<Eylea@wc.com<mailto:Eylea@wc.com>>
Subject: RE: In re aflibercept - May 10 submission m/c

Counsel,

Biocon/Mylan are in agreement with the revisions to the sealed filing proposal that were provided by Formycon/Celltrion/SB, and see no reason to include past filings in the sealed filing proposal.

Biocon/Mylan are available to meet and confer during the proposed times.

Regards,

Neil

Neil B. McLaughlin Ph.D. | Partner

NMclaughlin@rmmslegal.com<<mailto:NMclaughlin@rmmslegal.com>>

DIRECT | 312.222.7241

OFFICE | 312.527.2157

[cid:color-sm_5e876483-4c97-4ab1-9a8e-7f2446702a11.png]<<http://www.rmmslegal.com/>>

SIX WEST HUBBARD STREET | CHICAGO IL 60654

WWW.RMMSLEGAL.COM<<http://www.RMMSLEGAL.COM>>

This email message and any attachments are being sent by Rakoczy Molino Mazzochi Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient, please notify us immediately by replying to this message, and destroy all copies of this message and any attachments. Thank you.

From: Mascherin, Terri L. <TMascherin@jenner.com>

Sent: Monday, May 27, 2024 5:20 PM

To: Brett A. Postal <bpostal@rothwellfigg.com>

Cc: Patel, Priyata <Priyata.Patel@weil.com>; Mike Cottler <mcottler@geminilaw.com>; Shaun Van Horn <vanhorn@fr.com>; laurafairneny@quinnemanuel.com; John R. Labbe <jlabbe@marshallip.com>; Neil B. McLaughlin <NMclaughlin@rmmslegal.com>; Argall, Arthur <aargall@wc.com>; M710 Team <M710Team@rmmslegal.com>; Jamie.Obrien@steptoe-johnson.com; Gordon.Copland@steptoe-johnson.com; DG-Aflibercept <DG-Aflibercept@netorg8512690.onmicrosoft.com>; WFG-aflibercept@willkie.com; mhissam@hfdrlaw.com; Carl Shaffer <cshaffer@hfdrlaw.com>; Andrew Robey <arobey@hfdrlaw.com>; Max Gottlieb <mgottlieb@hfdrlaw.com>; QE - Samsung Bioepis <qe-samsungbioepis@quinnemanuel.com>; skl@schraderlaw.com; clt@simmermanlaw.com; fes@simmermanlaw.com; trey@simmermanlaw.com; SERVICE - Formycon Team <SERVICE-Formycon_Team@fr.com>; MGB-Amgen-ABP938 <MGB-Amgen-ABP938@marshallip.com>; ABP938 <ABP938@rothwellfigg.com>; regeneronpatent@lists.kelloggghansen.com; drpogue@cdkrlaw.com; sruby@cdkrlaw.com; Ashley Hardesty Odell <ahardestyodell@bowlesrice.com>; Kaitlyn McKitrick <kmckitrick@bowlesrice.com>; Eylea Biosimilars <Eylea.Biosimilars@weil.com>; Eylea@wc.com

Subject: Re: In re aflibercept - May 10 submission m/c

I suggest we address this at the same call, then.

Terri

On May 27, 2024, at 4:50 PM, Brett A. Postal <bpostal@rothwellfigg.com><<mailto:bpostal@rothwellfigg.com>>> wrote:

External Email - Do Not Click Links or Attachments Unless You Know They Are Safe

Hi Terri,

Thank you for the email.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.